Imidapril improves L-NAME-exacerbated nephrosclerosis with TGF-β1 inhibition in spontaneously hypertensive rats

Journal of Hypertension

Volumn 22, Issue 7, 2004, Pages 1389-1395

  Ono, Hidehiko ^a   Saitoh, Mayumi ^a   Ono, Yuko ^a   Ishimitu, Toshihiko ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Active caspase 3; Angiotensin converting enzyme inhibitor; Apoptosis; Imidapril; NG nitro L arginine methyl ester; Nephrosclerosis; Spontaneously hypertensive rats; Transforming growth factor 1; TUNEL

Indexed keywords

CASPASE 3; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL LABELING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DRUG SCREENING; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; GLOMERULOSCLEROSIS; GLOMERULUS; HISTOPATHOLOGY; IMMUNOHISTOLOGY; INHIBITION KINETICS; KIDNEY CELL; KIDNEY DISEASE; KIDNEY PARENCHYMA; MALE; NEPHROSCLEROSIS; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; URINARY EXCRETION;

EID: 3042716265     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000125458.28861.49     Document Type: Article

References (28)

1. Ono H, Ono Y, Frohlich ED. Nitric oxide synthase inhibition in spontaneously hypertensive rats: systemic, renal, and glomerular hemodynamics. Hypertension 1995; 26:249-255.
2. Ono Y, Ono H, Matsuoka H, Fujimori T, Frohlich ED. Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension 1999; 34:609-616.
3. Ono H, Ono Y, Ishimitsu T, Matsuoka H. Valsartan reduce ventricular interstitial fibrosis by caspase-3 activation in prolonged L-NAME treated SHR in vivo [abstract]. Circulation 2001; 104:ii-451.
4. Ono H, Ono Y, Frohlich ED. ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis with spontaneously hypertensive rats. Hypertension 1996; 27:176-183.
5. Nakamura Y, Ono H, Zhou X, Frohlich ED. Angiotensin type 1 receptor antagonist and ACE inhibition produce similar renoprotection in N-nitro-L-arginine methyl ester/spontaneously hypertensive rats, Hypertension 2001; 37:1262-1267.
6. Watanabe S, Ono H, Ishimitsu T, Matsuoka H, Ono Y, Fujimori T. Calcium antagonist inhibits glomerular cell apoptosis and injuries of L-NAME exacerbated nephrosclerosis in SHR. Hypertens Res 2000; 23:683-691.
7. Zhou X, Ono H, Ono Y, Frohlich ED. N-and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an L-NAME/SHR model. J Hypertens 2002; 20:993-1000.
8. Inada H, Ono H, Minami J, Ishimitsu T, Matsuoka H. Nipradilol prevents L-NAME-exacerbated nephrosclerosis with decreasing of caspase-3 expression in SHR. Hypertens Res 2002; 25:433-440.
9. Ono H, Ono Y, Takanohashi A, Matsuoka H, Frohlich ED. Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension 2001; 38:1300-1306.
10. Dimmeler S, Rippmann V, Weiland U, Haedeler J, Zeiher AM. Angiotensin II induces apoptosis of human endothelial cells: protective effect of nitric oxide. Circ Res 1997; 81:970-976.
11. de Gasparo M, Siragy HM. The AT2 receptor: fact, fancy, and fantasy. Regulatory Peptides 1999; 81:11-24.
12. Zhou X, Ono H, Ono Y, Frohlich ED. Renoprotection effects of omapatrilat are mediated partially by bradykinin. Am J Nephrol 2003; 23:214-221.
13. Francischetti A, Ono H, Frohlich ED. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998; 31:795-801.
14. Gibson UEM, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6:995-1001.
15. Duncan WG. Multiple range and multiple F test. Biometrics 1995; 11:1-42.
16. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304:339-343.
17. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effects of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118:129-138.
18. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-converting-Enzyme Inhibition in Progress Renal Insufficiency Study Group. N Engl J Med 1996; 334:939-945.
19. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet 1997; 349:1857-1863.
20. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. The African American Study of Kidney Disease and Hypertension Study Group. JAMA 2002; 20:2421-2431.
21. Kashiwagi M, Shinozaki M, Hirakata H, Tamaki K, Hirano T, Tokumoto M, et al. Locally activated rennin-angiotensin system associated with TGF-ß1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000; 11:616-624.
22. Boffa JJ, Lu Y, Racier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14:1132-1144.
23. Ono Y, Ono H, Frohlich ED. Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 1996; 14:823-828.
24. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol 1994; 266:F829-F842.
25. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, et al. Captopril-induced reduction of serum levels of transforming growth factor-β1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999; 34:818-823.
26. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994; 93:2431-2437.
27. Okado T, Terada Y, Tanaka H, Inoshita S, Nakao A, Sasaki S. Smad7 mediates transforming growth factor-β-induced apoptosis in mesangial cells. Kidney Int 2002; 62:1178-1186.
28. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Bottinger EP. Apoptosis in podocytes induced by TGF-β and Smad7. J Clin Invest 2001; 108:807-816.